Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

A large-scale computational study of inhibitor risk in non-severe haemophilia A

(2014) Adrian J. Shepherd et al.   BRITISH JOURNAL OF HAEMATOLOGY

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

(2014) S. R. Lentz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

(2013) S. Zollner et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

(2013) Vera Brinks et al.   PHARMACEUTICAL RESEARCH

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

(2012) S. F. J. Whelan et al.   BLOOD

F8haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

(2012) J. Schwarz et al.   HAEMOPHILIA

Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective

(2012) Z. E. SAUNA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

(2012) J. N. MAHLANGU et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Vatreptacog Alfa from Conception to Clinical Proof of Concept

(2012) Egon Persson et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

(2011) A. TIEDE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

(2011) ERICH V. DE PAULA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A

(2010) Donald F Brophy et al.   BLOOD COAGULATION & FIBRINOLYSIS

Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A

(2009) A. PAVLOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

(2009) Rafael Ponce et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Single 270 μg kg−1-dose rFVIIa vs. standard 90 μg kg−1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

(2008) G. YOUNG et al.   HAEMOPHILIA

The Origins of Enhanced Activity in Factor VIIa Analogs and the Interplay between Key Allosteric Sites Revealed by Hydrogen Exchange Mass Spectrometry

(2008) Kasper D. Rand et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

(2008) J. MØSS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS